As a result of the acquisition of InGen BioSciences by Exonhit, the new Diaxonhit group benefits from the complementary capabilities derived from both companies’ business models. Its growth is based on the continued development of its distribution activities, and the development of its high added value proprietary innovative diagnostic products.
Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis.
The group is currently marketing two proprietary products, TQS® (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe.

Paris, FR
Size (employees)
82 (est)-7%
Diaxonhit was founded in 1997 and is headquartered in Paris, FR

Diaxonhit Office Locations

Diaxonhit has offices in Paris and Rockville
Paris, FR (HQ)
65 Boulevard Masséna
Rockville, US
450 1 Research Ct
Show all (2)

Diaxonhit Financials and Metrics

Diaxonhit Financials


Market capitalization (31-Oct-2017)

20.8 m

Closing share price (31-Oct-2017)

Diaxonhit's current market capitalization is €20.8 m.
Show all financial metrics

Diaxonhit Market Value History

Diaxonhit's Web-traffic and Trends

Diaxonhit Online and Social Media Presence

Diaxonhit Company Life and Culture

You may also be interested in